Global Lab-synthesized Heparin Market Overview
The Lab-synthesized Heparin Market Size was valued at USD 7.8 billion in 2023. The industry is projected to grow from USD 8.03 billion in 2024 to USD 9.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.00% during the forecast period (2024 - 2032). Rising cardiovascular disease and other chronic illnesses and significant demand for anticoagulant products are the primary market drivers propelling the market's expansion.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Lab-synthesized Heparin Market Trends
-
Rising demand for low molecular weight heparin is driving the market growth
Intravenous or subcutaneous organization of anticoagulant low molecular weight heparin (LMWH) is conceivable. For example, enoxaparin and dalteparin capability by first enacting antithrombin III, which then, at that point, deactivates thrombin and component Xa to accomplish its impact. The British National Formulary (BNF) has approved Low Molecular Weight Heparin (LMWH). The National Institute for Health and Care Excellence (NICE) has stated that LMWHs can be used to treat venous thromboembolism in pregnancy, DVT, and pulmonary embolism (PE) in non-pregnant women, as well as prophylactic treatment for deep vein thrombosis (DVT) in patients in medium- and high-risk categories (medical, orthopedic, and surgical patients). Due to the widespread usage of LMWH around the world, the LMWH market sector is anticipated to comprise a sizable portion of the research market, which is driving the market CAGR.
Furthermore, because LMWH has a variety of uses for older people, the growing geriatric population is anticipated to support segment expansion. For example, low molecular weight heparin (LMWH) is widely used. According to an article published by PubMed Central in December 2021, it is advised by a European guideline for senior patients with renal failure or during the perioperative phase of the knee or hip replacement with no limits on particular kinds.
The organizations are consistently engaged in creating and showcasing new prescriptions because of the developing weight of persistent illnesses, which is additionally anticipated to help development in the LMWH fragment all through the study's forecast period. For example, in August 2022, the FDA endorsed Momenta Drugs, Inc.'s s—m-Enoxaparin item. Along with Sandoz, the generics arm of Novartis AG, Momenta is making M-Enoxaparin, an innovative, improved generic version of Lovenox. Likewise, in May 2021, Dr. Reddy's Labs Ltd. sent off Ertapenem for Infusion, a therapeutic equivalent generic form of INVANZ (ertapenem for infusion) for infusion, 1 g/vial, 1 g/vial after getting an endorsement from the FDA. Thus, due to the previously mentioned factors, it is likely that during the review's projected period, the low sub-atomic weight heparin section will hold a sizable market share.
Moreover, the high use of plasma in the drug business by key players is expected to facilitate market interest. For example, in March 2023, Takeda's significant investment of around 100 billion yen (USD 754 million) in building another assembling facility for plasma-determined treatments (PDTs) in Osaka, Japan, implies a huge market development driver. This significant responsibility reflects the drug business' rising dependence on plasma-derived items, including anticoagulants like heparin, highlighting the business' commitment to satisfying the rising need for fundamental medicines. Takeda's essential move lines up with the high utilization of plasma in the drug area, stressing the significant role of anticoagulants in addressing patient necessities and contributing to the market's development. Thus driving the Lab-synthesized Heparin market revenue.
Lab-synthesized Heparin Market Segment Insights
Lab-synthesized Heparin Product Insights
Based on Product, the Lab-synthesized Heparin Market segmentation includes low molecular weight heparin and unfractionated heparin. In 2023, the low molecular weight heparin segment dominated the market. The increasing prevalence of deep vein thrombosis has expanded the requirement for low molecular weight heparin. According to the CDC, around 60,000-100,000 Americans pass on from this condition consistently. In addition, low molecular weight heparin has a longer shelf-life, reduces and eliminates medical clinic stays, and can be self-controlled at home through subcutaneous infusion, which favors its mass adoption.
The unfractionated heparin category is anticipated to be the fastest growing. UFH is frequently utilized as an anticoagulant in surgical treatments, especially those requiring cardiopulmonary bypass or vascular surgery. It lowers the chance of postoperative problems, including thrombosis and embolism, by assisting in the prevention of blood clot formation both during and after surgery.
Figure 1: Lab-synthesized Heparin Market, by Product, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Lab-synthesized Heparin Source Insights
Based on Source, the Lab-synthesized Heparin Market segmentation includes porcine and bovine. In 2023, the porcine category generated the most income. Porcines are widely used in the manufacturing of heparin, particularly LMWH, like enoxaparin, which explains this. Porcine heparin's potent pharmacological and biochemical actions result in a stronger anticoagulant activity (180–220 units/mg) than bovine heparin's (130–150 units/mg). Heparins from pork are 30%–50% more effective than those from cows. Moreover, in unfavorable circumstances, pig heparin is simpler to neutralize.
The lab-synthesized Heparin segment market for bovines is anticipated to grow fastest during the forecast period. Heparin from cows only reaches 76% of the maximal plasma concentration, which is less effective than heparin from pigs. Bovine heparin does not boost the anticoagulant capability of porcine heparin. However, it does achieve a 1.5-fold greater plasma concentration when expressed in weight.
Lab-synthesized Heparin Application Insights
Based on Application, the Lab-synthesized Heparin Market segmentation includes venous thromboembolism, atrial fibrillation/flutter, coronary artery disease, and other applications. The venous thromboembolism category leads the market. Heparin is becoming more necessary due to the rising incidence of venous thromboembolism. The market is also expanding as a result of recent developments in the creation of innovative heparin formulations to get around the limitations of current venous thromboembolism treatments. There is a strong growth potential for the heparin market as a result of several industry participants concentrating on developing improved heparin capabilities to expand their footprint.
The Lab-synthesized Heparin market’s coronary artery disease segment is anticipated to grow fastest during the projection period. In acute myocardial infarction instances, lab-synthesized heparin is given to limit myocardial damage and stop coronary thrombosis from spreading. To obtain the best antithrombotic benefits, it is frequently used in combination with antiplatelet medications like aspirin and P2Y12 inhibitors.
Lab-synthesized Heparin Distribution Channel Insights
Based on Distribution Channels, the Lab-synthesized Heparin Market segmentation includes hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy category leads the market. Lab-synthesized heparin's potential inclusion in the hospital formulary is assessed by hospital pharmacies in partnership with pharmacy and therapeutics (P&T) committees. To evaluate the suitability, security, and financial viability of heparin treatment inside the facility, they do drug usage assessments.
The retail segment of the Lab-Synthesized Heparin market is predicted to develop quickly over the projected period. Lab-synthesized heparin products may be available for patients who need to get self-administered injections or infusions at home from retail pharmacies that specialize in home health care supplies. Patients undergoing treatment at these pharmacies may receive instruction on safe administration practices.
Lab-synthesized Heparin Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Lab-synthesized Heparin market will dominate this market. Owing to the US, the lab-synthesized market is likewise expected to develop because of the rising number of item endorsements in the country and ongoing headways. For example, in February 2022, Compact Disc Bioparticles, a top producer and supplier of different medication conveyance labor and products, sent off a few Heparin items, including Heparin Biotin, Heparin Amine, and Heparin Thiol, and made them accessible to help drug conveyance research. In this manner, because of the previously mentioned factors, the North American region is assessed to hold a sizable extent of the overall heparin market, with the US being the biggest country inside it during the review's gauge time frame.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Lab-Synthesized Heparin Market Share By Region 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Lab-synthesized Heparin market accounts for the second-largest market share. The growing occurrence of venous thromboembolism, ischemic coronary illness, and other cardiovascular sicknesses that lead to blood cluster arrangement has expanded the requirement for heparin in Europe. According to the European Culture of Cardiology, cardiovascular issues lead to around 3.9 million mortalities yearly in the area. Additionally, regional development can likewise be attributed to rising awareness about clever oral anticoagulants. Further, the German Lab-synthesized Heparin market held the largest market share, and the UK Lab-synthesized Heparin market was the fastest-growing market in the European region.
The Asia-Pacific Lab-synthesized Heparin Market is expected to grow at the fastest CAGR from 2024 to 2032. Cardiovascular sicknesses stand as the predominant reason for death and handicap in the Asia Pacific district, representing a significant economic burden on health systems. The NCBI article distributed in June 2023, "The report on cardiovascular wellbeing and sicknesses in China 2021: a refreshed synopsis," underlines this test, uncovering that around 330 million people in China are impacted by different cardiovascular circumstances. Moreover, China’s Lab-synthesized Heparin market held the largest market share, and the Indian Lab-synthesized Heparin market was the fastest-growing market in the Asia-Pacific region.
Lab-synthesized Heparin Key Market Players & Competitive Insights
The Lab-synthesized Heparin market will continue to grow due to major companies in the industry making significant R&D investments to extend their product ranges. Significant market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and cooperation with other organizations. Market participants also engage in various strategic actions to broaden their global footprint. The Lab-synthesized Heparin sector must provide affordable products & services to grow and thrive in a more cutthroat and dynamic market.
One of the main strategies manufacturers use in the worldwide Lab-synthesized Heparin market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. Some of the biggest medical benefits in recent years have come from the Lab-synthesized Heparin sector. Major players in the Lab-synthesized Heparin market, including Fresenius Kabi, Techdow USA, B. Bruan, Amphastar, Leo Pharma, Sanofi, Pfizer, Shenzhen Hepalink, Changzhou Qianhong Biopharma, and Yantai Dongcheng Biochemicals Co., Ltd., and others, are engaging in research and development activities in an effort to boost market demand.
Pharmaceuticals and medical devices are developed, produced, and marketed by Fresenius Kabi AG, a subsidiary of Fresenius SE & Co KGaA. Clinical nutrition items, medical equipment, infusion therapy products, and intravenously delivered medications are all part of its product line. The therapeutic areas in which the firm specializes include blood volume replacement, fluid management, anesthesia, severe illness, liver and kidney insufficiencies, maldigestion or malabsorption, diabetes mellitus, and pediatrics. The treatment of severely and chronically sick patients is indicated for its goods and services. Fresenius Kabi carries out sales and marketing activities through direct offices throughout the globe. The well-known infusion treatment business Ivenix, Inc. was purchased by the well-known pharmaceutical company Fresenius Kabi in May 2022.
Techdow USA is an energetic, superior presentation pharmaceutical organization that is focused on quality and dependability to their patients and clients. They create, assemble, and sell basic FDA-endorsed items for use in hospital and clinical settings. They are upward coordinated in raw materials and can convey hard-to-source items at a competitive cost. Techdow USA is among the quickest developing organizations in their industry and is continuously searching for ways to improve and set another superior execution standard. They are energetic about significantly impacting patients and bringing effective medicines to market. Techdow USA has innovation and a foundation that can bring unique customer solutions that were not previously accessible to these business sectors. These incorporate exceptional access and conveyance choices during basic market shortage situations. Techdow USA Incorporated introduced low molecular weight heparin in strengths of 150 mg, 120 mg, 100 mg, 80 mg, 60 mg, 40 mg, and 30 mg in June 2023.
Key companies in the Lab-synthesized Heparin market include
- Fresenius Kabi
- Techdow USA
- Bruan
- Amphastar
- Leo Pharma
- Sanofi
- Pfizer
- Shenzhen Hepalink
- Changzhou Qianhong Biopharma
- Yantai Dongcheng Biochemicals Co., Ltd.
Lab-synthesized Heparin Industry Developments
February 2024: B. Bruan, a business that advances smart infusion treatment and pain management Heparin was introduced in 2000 units in 0.9% sodium chloride injection.
February 2022: Injectables manufacturer Techdow USA Inc. introduced Heparin Sodium Injection, USP, in the United States, improving the business's market position.
Lab-synthesized Heparin Market Segmentation
Lab-synthesized Heparin Product Outlook
- Low Molecular Weight Heparin
- Unfractionated Heparin
Lab-synthesized Heparin Source Outlook
Lab-synthesized Heparin Application Outlook
- Venous Thromboembolism
- Atrial Fibrillation/Flutter
- Coronary Artery Disease
- Other Applications
Lab-synthesized Heparin Distribution Channel Outlook
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Lab-synthesized Heparin Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
| Report Attribute/Metric |
Details |
| Market Size 2023 |
USD 7.8 Billion |
| Market Size 2024 |
USD 8.03 Billion |
| Market Size 2032 |
USD 9.8 Billion |
| Compound Annual Growth Rate (CAGR) |
3.00% (2024-2032) |
| Base Year |
2023 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2019-2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Product, Source, Application, Distribution Channel, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Fresenius Kabi, Techdow USA, B. Bruan, Amphastar, Leo Pharma, Sanofi, Pfizer, Shenzhen Hepalink, Changzhou Qianhong Biopharma, and Yantai Dongcheng Biochemicals Co., Ltd. |
| Key Market Opportunities |
· Expansion of therapeutic applications and regenerative medicine and tissue engineering |
| Key Market Dynamics |
· Rising cardiovascular disease and other chronic illnesses and a significant demand for anticoagulant products. |
Frequently Asked Questions (FAQ) :
The Lab-synthesized Heparin Market size was valued at USD 7.8 Billion in 2023.
The global market is projected to grow at a CAGR of 3.00% during the forecast period, 2024-2032.
North America had the largest share of the global market.
The key players in the market are Fresenius Kabi, Techdow USA, B. Bruan, Amphastar, Leo Pharma, Sanofi, Pfizer, Shenzhen Hepalink, Changzhou Qianhong Biopharma, and Yantai Dongcheng Biochemicals Co., Ltd.
The Low Molecular Weight Heparin category dominated the market in 2023.
The Porcine category had the largest share of the global market.
